利奈唑胺治疗ICU革兰阳性球菌感染的疗效及安全性观察

Efficacy and safety of linezolid in the treatment of Gram positive cocci infection in ICU

目的探讨ICU革兰阳性球菌感染给予利奈唑胺治疗的临床疗效和安全性。方法选取ICU革兰阳性球菌感染患者124例作为研究对象,根据随机数字表法分为研究组和对照组,每组62例。研究组给予利奈唑胺治疗,对照组给予万古霉素治疗,观察两组患者的临床疗效及不良反应发生率,并进行统计学分析。结果治疗后,研究组总有效58例,总有效率为93.55%,对照组总有效50例,总有效率为80.65%,差异有统计学意义(P<0.05);研究组发生不良反应2例,不良反应发生率为3.24%,对照组发生不良反应7例,不良反应发生率为11.29%,差异有统计学意义(P<0.05)。结论利奈唑胺可有效控制革兰阳性球菌感染患者,提升临床治疗疗效,且治疗过程中安全性较高,值得临床推广应用。

Objective To investigate the clinical efficacy and safety of linezolid in the treatment of gram positive cocci infection in ICU. Methods One hundred and twenty-four cases of patients with gram positive coccus infection were select- ed as the research object, all the patients were randomly divided into study group and reference group, with 62 cases in each group respectively. The study group was given Linezolid for treatment, and the control group was given Vancomycin for treatment, the clinical effects and adverse reaction rates of the two groups were compared, and conducted statistical analysis as well. Results The total effective number of patients in the study group was 58 cases, with treatment effective rate of 93.55%, and the total effective number of patients in the reference group was 50 cases, with treatment effective rate of 80.65%. There was significant difference （ P 〈 0. 05 ）. The total number of patients with adverse reaction in the study group was 2 eases, with adverse reaction rate of 3.24% , and was 7 cases in reference group with adverse reaction rate of 11.29%. There was significant difference （ P 〈 0.05 ）. Conclusion Linezolid can effectively control patients with gram positive coccus infection, and it can improve the clinical curative effect with higher safety in the process of treatment, so that it is worthy of clinical application.